Biotech · Private company
Laboratoires Thea
Track this companyFree. Adds Laboratoires Thea to your Dealase workspace and tells you when its record changes.
Clinical trials113 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline15
- Bimatoprost OphthalmicPhase 3 · GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- QR-421aPhase 3 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- sepofarsenPhase 3 · Leber Congenital Amaurosis 10ClinicalTrials.gov · fetched Nov 12, 2026
- Sham-procedurePhase 3 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- UltevursenPhase 3 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- Intravitreal Injection of UltevursenPhase 2 · Retinitis Pigmentosa (RP)ClinicalTrials.gov · fetched Nov 12, 2026
- Kinezodianone R hydrochloridePhase 2 · GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- No intervention, will not receive any active study interventionPhase 2 · Retinitis Pigmentosa (RP)ClinicalTrials.gov · fetched Nov 12, 2026
- QR-110Phase 2 · Leber Congenital Amaurosis 10ClinicalTrials.gov · fetched Nov 12, 2026
- QR-110Phase 2 · Leber's Congenital AmaurosisClinicalTrials.gov · fetched Nov 12, 2026
- Rhopressa®Phase 2 · GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- RNA antisense oligonucleotide for intravitreal injectionPhase 2 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- T4090 0.2%Phase 2 · GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- T4090 0.3%Phase 2 · GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- Bimatoprost OphthalmicPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)PHASE3 · RECRUITING · started Jun 4, 2025ClinicalTrials.gov NCT06891443 · fetched Nov 12, 2026
- Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GenePHASE2 · ACTIVE_NOT_RECRUITING · started Dec 11, 2024ClinicalTrials.gov NCT06627179 · fetched Nov 12, 2026
- Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionPHASE2 · COMPLETED · started Aug 5, 2024ClinicalTrials.gov NCT06394973 · fetched Nov 12, 2026
- Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy VolunteersPHASE1 · COMPLETED · started Feb 27, 2023ClinicalTrials.gov NCT05729594 · fetched Nov 12, 2026
- Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 5, 2022ClinicalTrials.gov NCT05389267 · fetched Nov 12, 2026
- Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous PatientsPHASE3 · COMPLETED · started Jun 22, 2022ClinicalTrials.gov NCT05397600 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)PHASE2_PHASE3 · TERMINATED · started Dec 15, 2021ClinicalTrials.gov NCT05176717 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)PHASE2_PHASE3 · TERMINATED · started Dec 8, 2021ClinicalTrials.gov NCT05158296 · fetched Nov 12, 2026
- An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis PigmentosaPHASE2 · TERMINATED · started Sep 16, 2021ClinicalTrials.gov NCT05085964 · fetched Nov 12, 2026
- Extension Study to Study PQ-110-001 (NCT03140969)PHASE1_PHASE2 · TERMINATED · started May 13, 2019ClinicalTrials.gov NCT03913130 · fetched Nov 12, 2026
- Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GenePHASE1_PHASE2 · COMPLETED · started Oct 16, 2017ClinicalTrials.gov NCT03140969 · fetched Nov 12, 2026